Paediatric Solid Tumour Biology and Therapeutics Group

Professor Louis Chesler’s group is investigating the genetic causes for the childhood cancers, neuroblastoma, medulloblastoma and rhabdomyosarcoma. 

Research, projects and publications in this group

Our group's aim is to improve the treatment and survival of children with neuroblastoma, medulloblastoma and rhabdomyosarcoma.

The goal of our laboratory is to improve the treatment and survival of children with neuroblastoma, medulloblastoma and rhabdomyosarcoma, three paediatric solid tumours in which high-risk patient cohorts can be defined by alterations in a single oncogene. We focus on the role of the MYCN oncogene, since aberrant expression of MYCNis very significantly associated with high-risk in all three diseases and implies that they may have a common cell-of-origin.

Elucidating the molecular signalling pathways that control expression of the MYCN oncoprotein and targeting these pathways with novel therapeutics is a major goal of the laboratory. We use a variety of innovative preclinical drug development platforms for this purpose.

Technologically, we focus on genetically engineered cancer models incorporating novel imaging (optical and fluorescent) modalities that can be used as markers to monitor disease progression and therapeutic response.

Our group has several key objectives:

  • Mechanistically dissect the role of the MYCN oncogene, and other key oncogenic driver genes in poor-outcome paediatric solid tumours (neuroblastoma, medulloblastoma, rhabdomyosarcoma).
  • Develop novel therapeutics targeting MYCN oncoproteins and other key oncogenic drivers
  • Develop improved genetic cancer models dually useful for studies of oncogenesis and preclinical development of novel therapeutics.
  • Use such models to develop and functionally validate optical imaging modalities useful as surrogate markers of tumour progression in paediatric cancer.

Professor Louis Chesler

Clinical Senior Lecturer/Group Leader:

Paediatric Solid Tumour Biology and Therapeutics Professor Louis Chesler (Profile pic)

Professor Louis Chesler is working to understand the biology of children’s cancers and use that information to discover and develop new personalised approaches to cancer treatment. His work focuses on improving the understanding of the role of the MYCN oncogene.

Researchers in this group

.

Email: [email protected]

Location: Sutton

.

Phone: +44 20 3437 6124

Email: [email protected]

Location: Sutton

.

Email: [email protected]

Location: Sutton

.

Email: [email protected]

Location: Sutton

.

Phone: +44 20 3437 3617

Email: [email protected]

Location: Sutton

.

Phone: +44 20 8722 4186

Email: [email protected]

Location: Sutton

.

Phone: +44 20 3437 3501

Email: [email protected]

Location: Sutton

.

Email: [email protected]

Location: Sutton

.

Phone: +44 20 8722 4361

Email: [email protected]

Location: Sutton

.

Email: [email protected]

Location: Sutton

.

Phone: +44 20 3437 6118

Email: [email protected]

Location: Sutton

.

Phone: +44 20 3437 6021

Email: [email protected]

Location: Sutton

.

Phone: +44 20 3437 6196

Email: [email protected]

Location: Sutton

.

Phone: +44 20 3437 6258

Email: [email protected]

Location: Sutton

.

Email: [email protected]

Location: Sutton

.

Phone: +44 20 3437 6121

Email: [email protected]

Location: Sutton

.

Phone: +44 20 8722 4527

Email: [email protected]

Location: Sutton

.

OrcID: 0000-0003-3977-7020

Phone: +44 20 3437 6109

Email: [email protected]

Location: Sutton

I obtained an MSci in Biochemistry from the University of Glasgow in 2018. In October 2018 I joined the labs of Dr Michael Hubank and Professor Andrea Sottoriva to investigate the use of liquid biopsy to monitor clonal frequency and emergence of resistance mutations in paediatric cancers.

.

Email: [email protected]

Location: Sutton

.

Phone: +44 20 3437 6358

Email: [email protected]

Location: Sutton

.

Phone: +44 20 3437 6131

Email: [email protected]

Location: Sutton

.

Email: [email protected]

Location: Sutton

Professor Louis Chesler's group have written 113 publications

Most recent new publication 4/2025

See all their publications

Vacancies in this group

Working in this group

Postdoctoral Training Fellow

  • Chelsea
  • Structural Biology
  • Salary Range: £45,600 - £55,000 per annum
  • Fixed term

Under the leadership of Claudio Alfieri, we are seeking to appoint a Postdoctoral Training Fellow to join the Molecular Mechanisms of Cell Cycle Regulation Group at the Chester Beatty Laboratories, Fulham Road in London. This project aims to investigate the molecular mechanisms of cell cycle regulation by macromolecular complexes involved in cell proliferation decisions, by combining genome engineering, proteomics and in situ structural biology. For general information on Post Doc's at The ICR can be found here. Key Requirements The successful candidate must have a PhD in cellular biochemistry and experience in Cryo-EM and CLEM is desirable. The ICR has a workforce agreement stating that Postdoctoral Training Fellows can only be employed for up to 7 years as PDTF at the ICR, providing total postdoctoral experience (including previous employment at this level elsewhere) does not exceed 7 years Department/Directorate Information: The candidate will work in the Molecular Mechanisms of Cell Cycle Regulation Group within the ICR Division of Structural Biology headed by Prof. Laurence Pearl and Prof. Sebastian Guettler. The division has state-of-the-art facilities for protein expression and biophysics/x-ray crystallography, in particular the Electron Microscopy Facility is equipped with a Glacios 200kV with Falcon 4i detector with Selectris energy filter and the ICR has access to Krios microscopes via eBIC and the LonCEM consortium. We encourage all applicants to access the job pack attached for more detailed information regarding this role. For an informal discussion regarding the role, please contact Claudio Alfieri via Email on [email protected]

Clinical Research Fellow

  • Sutton
  • Clinical Studies
  • circa £55,329.00
  • Fixed term

Applications are invited for the post of Clinical Research Fellow in the Prostate Cancer Targeted Therapy Group (PCTTG) at The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust to contribute to the discovery, development and delivery of the next generation of treatments, technologies and methodology into clinical care. This post is an excellent opportunity to be centrally involved in the management of patients with advanced prostate cancer enrolled in clinical trials of experimental anti-cancer drugs. In addition, the applicant will be encouraged to become involved in translational research that could lead to a PhD and will gain experience in translational and clinical research including the conduct of clinical trials and manuscript writing. To be considered applicants must meet the following essential criteria: Full registration with the General Medical Council, Acquisition of MRCP, and Clinical experience in managing cancer patients. Department/Directorate Information The PCTTG, under the leadership and guidance of Professor Johann de Bono and Dr Adam Sharp, has led on the development of many of the new drugs currently used for the management of advanced prostate cancer including abiraterone, cabazitaxel, enzalutamide, olaparib and Lutetium PSMA. The Unit is based at the Royal Marsden in the Oak Cancer Centre, a day-care area with outpatient facilities exclusively dedicated to the care and treatment of patients enrolled in clinical trials and is closely linked to our translational research laboratories at The Institute of Cancer Research. What we offer A dynamic and supportive research environment Access to state-of-the-art facilities and professional development opportunities Collaboration with leading researchers in the field Competitive salary and pension We encourage all applicants to access the job pack attached for more detailed information regarding this role. For an informal discussion regarding the role, please contact Professor Johann de Bono via email on [email protected]

Industrial partnership opportunities with this group

Opportunity: A novel test for predicting future cancer risk in patients with inflammatory bowel disease

Commissioner: Professor Trevor Graham

Recent discoveries from this group

09/01/25

The Institute of Cancer Research, London, strongly welcomes the decision by NICE to recommend that the targeted drug olaparib can be used for locally advanced or metastatic breast cancer.

The judgement makes this pioneering treatment available on the NHS for people with HER2-negative breast cancer, caused by faulty BRCA1 or BRCA2 genes, which has advanced or spread following chemotherapy. The treatment offers the chance of longer, healthier lives for thousands of patients.

More patients can now benefit from olaparib

Olaparib is a precision medicine that belongs to a class of drugs called PARP inhibitors. It targets the specific biology of cancers linked to faulty BRCA1 or BRCA2 genes and works across many different cancer types.

Olaparib has been available on the NHS in England and Wales for women with early-stage, high-risk breast cancer with inherited mutations in BRCA1 or BRCA2 since April 2023. Today’s news means that olaparib’s benefits can reach NHS patients with advanced breast cancer, whose disease has returned after previous treatment.

The ICR's role in the development of olaparib

The Institute of Cancer Research (ICR) has played a crucial role in the development of olaparib. ICR scientists were the first to demonstrate that cancer cells with mutations in BRCA1 or BRCA2 were highly susceptible to PARP inhibitors like olaparib.

Clinical trials of olaparib, led by researchers from the ICR and The Royal Marsden NHS Foundation Trust, then showed that olaparib was effective for patients with a range of cancers associated with BRCA1 or BRCA2 mutations.

Professor Andrew Tutt was part of the ICR team at the Breast Cancer Now Toby Robins Research Centre that carried our early laboratory work which revealed how PARP inhibitors could target cancers with mutations in BRCA1 and BRCA2. He was the lead Principal Investigator of the phase III OlympiA trial, which revealed the benefits of olaparib in improving the chances of surviving high risk early-stage breast cancer, which led to the decision by NICE in 2023 to recommend olaparib for these patients.

'Another important therapy option for our patients'

Professor Andrew Tutt, Director of the Breast Cancer Now Toby Robins Research Centre at The Institute of Cancer Research, London and King’s College London, said:

“Locally advanced or metastatic HER2-negative breast cancer remains a devastating diagnosis. For those with this form of breast cancer and with inherited BRCA-mutations, the OlympiAD phase III trial demonstrated how olaparib – a PARP inhibitor that targets the mutated BRCA genes in cancer cells – can significantly delay cancer progression or death compared to standard chemotherapies.

“These results underpinned this positive NICE recommendation, which now provides another important oral targeted therapy option for our patients with this challenging diagnosis. This emphasises the importance of accessing genetic testing, so that these targeted drugs can reach the patients who will benefit from them.”

Professor Kristian Helin, Chief Executive of The Institute of Cancer Research, London said:

“Olaparib was the first cancer drug in the world to target an inherited genetic fault, and I am pleased that today’s announcement means that more patients will be able to access it on the NHS. Following the earlier recommendation for olaparib to treat early breast cancer, patients with advanced or metastatic breast cancer who are in desperate need of better treatment options will now be able to receive the targeted therapy.

“I’m proud of the decades of research at the ICR that have underpinned this achievement. Our scientists worked to understand and target the underlying cause of these inherited cancers – involving partnerships between academia, industry and charities across the world to deliver clinical trials – which has led us to a cutting-edge treatment which exploits the very mutation that caused the cancer.”

Olaparib is a game-changing treatment for many people with cancers linked to inherited BRCA1 and BRCA2 genes.

Find out how olaparib is transforming patients' lives.